Fundraising Fox

Vaxcyte

NASDAQ: PCVX

6 known investors

vaxcyte.com

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.

BiotechHealthtech

Investors · 6

Competitors · 3

by search overlap

Companies competing with Vaxcyte for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Vaxcyte do?
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.
Who are Vaxcyte's investors?
Vaxcyte's investors include BioRock Ventures, CTI Life Sciences Fund L.P., Foresite Capital, Frazier Life Sciences, Longitude Capital, RA Capital.